At Neobe Therapeutics we are engineering tumour-colonizing bacteria that will disrupt tumour micro environment barriers and enable immunotherapies in patients with immune-excluded tumours.
Only around 20% of patients with solid tumors are estimated to currently benefit from immunotherapies. Multiple factors contribute to this low level of efficacy. Chief among them is the existence of an immunosuppressive microenvironment that leads to the generation of immune "cold" tumours.
At Neobe we are harnessing the synthetic biology toolkit to engineer tumour-colonizing bacteria that locally disrupt this microenvironment. By acting locally within the tumor, these products avoid systemic toxicities while increasing drug efficacy. Disrupting these barriers and increasing immune cell infiltration in "cold" tumours will enable the success of immunotherapies in current non-responders.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Shepherd's Bush Market, Old Laundry Yard,unit G,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Coordinator jobs.
- HQ
- London, England
Neobe Therapeutics Questions
Neobe Therapeutics's website is https://www.neobetherapeutics.com/
Neobe Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/neobe-therapeutics
Neobe Therapeutics has
12 employees.
View email and phone details for 12
employees at Neobe Therapeutics.
Neobe Therapeutics's industry is
Biotechnology Research
Neobe Therapeutics's top competitors are
Curve Therapeutics,
Infinitopes,
Creasallis,
Mosaic Tx,
199 Biotechnologies,
Kenai Therapeutics,
Laverock Therapeutics,
Rinri Therapeutics,
Enedra Therapeutics,
Xap Therapeutics.
Neobe Therapeutics's categories are Biotechnology Research
Neobe Therapeutics's founding year is 2021
